Evercore ISI downgraded Intellia Therapeutics (NTLA) to In Line from Outperform with a price target of $8, down from $17. The firm sees a “narrow” path to valuation upside after the company’s cardiomyopathy of transthyretin-mediated amyloidosis program showed a severe liver toxicity event. Evercore is unsure when further clarity on the ATTR program will come.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Reports Favorable Phase 1 Data for Nex-Z
- Intellia announces ‘positive’ follow-up data from ongoing Phase 1 nex-z trial
- Intellia Therapeutics price target lowered to $14 from $25 at Truist
- Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat
- Intellia Therapeutics price target lowered to $15 from $18 at H.C. Wainwright